全文获取类型
收费全文 | 246512篇 |
免费 | 20810篇 |
国内免费 | 5544篇 |
专业分类
耳鼻咽喉 | 1920篇 |
儿科学 | 3539篇 |
妇产科学 | 3576篇 |
基础医学 | 26909篇 |
口腔科学 | 4382篇 |
临床医学 | 26783篇 |
内科学 | 29319篇 |
皮肤病学 | 2601篇 |
神经病学 | 20391篇 |
特种医学 | 27865篇 |
外国民族医学 | 19篇 |
外科学 | 19662篇 |
综合类 | 30926篇 |
现状与发展 | 22篇 |
一般理论 | 8篇 |
预防医学 | 15778篇 |
眼科学 | 3368篇 |
药学 | 27142篇 |
106篇 | |
中国医学 | 12798篇 |
肿瘤学 | 15752篇 |
出版年
2024年 | 235篇 |
2023年 | 3355篇 |
2022年 | 4893篇 |
2021年 | 9831篇 |
2020年 | 9043篇 |
2019年 | 8876篇 |
2018年 | 8795篇 |
2017年 | 9764篇 |
2016年 | 10027篇 |
2015年 | 9452篇 |
2014年 | 12379篇 |
2013年 | 15565篇 |
2012年 | 13277篇 |
2011年 | 15523篇 |
2010年 | 10663篇 |
2009年 | 10890篇 |
2008年 | 12316篇 |
2007年 | 13092篇 |
2006年 | 12139篇 |
2005年 | 11056篇 |
2004年 | 9464篇 |
2003年 | 8152篇 |
2002年 | 6371篇 |
2001年 | 5866篇 |
2000年 | 4923篇 |
1999年 | 4032篇 |
1998年 | 3217篇 |
1997年 | 3220篇 |
1996年 | 2859篇 |
1995年 | 2677篇 |
1994年 | 2491篇 |
1993年 | 2085篇 |
1992年 | 1866篇 |
1991年 | 1684篇 |
1990年 | 1440篇 |
1989年 | 1154篇 |
1988年 | 1092篇 |
1987年 | 998篇 |
1986年 | 892篇 |
1985年 | 1247篇 |
1984年 | 994篇 |
1983年 | 747篇 |
1982年 | 766篇 |
1981年 | 633篇 |
1980年 | 614篇 |
1979年 | 484篇 |
1978年 | 302篇 |
1977年 | 261篇 |
1976年 | 247篇 |
1975年 | 186篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
11.
12.
目的 测定儿童1型糖尿病(T1DM)患者骨密度(BMD),分析探讨骨密度变化的影响因素。方法 选取于2018年1月—2021年6月于我院收治的儿童1型糖尿病患者76例,收集性别、年龄、发病年龄、身高、体重、BMI、病程等基本资料,检测空腹血糖、空腹C肽、糖化血红蛋白(HbA1c)、血碳酸氢根(HCO3-)、血清碱性磷酸酶(ALP),应用双能X线吸收测定法测定骨密度,获取Z值。结果 76例儿童1型糖尿病患者骨密度Z值为-0.93±2.14。HbA1c、病程与骨密度Z值呈负相关,差异具有统计学意义(分别B=-0.334,P<0.001;B=-0.191,P=0.017)。结论 儿童1型糖尿病患者骨密度低于健康儿童,血糖控制不良、病程长是1型糖尿病儿童骨密度减低的危险因素。 相似文献
13.
【摘要】目的 探讨二维斑点追踪显像技术(2D-STI)评估新生儿窒息合并心肌损害后左心室整体及局部心肌的纵向收缩功能在早期诊断窒息新生儿心肌损害中的临床价值。方法 选择2019年07月至2020年12月期间在右江民族医学院附属医院新生儿科住院的足月窒息新生儿61例,经临床确诊合并心肌损害,根据Apgar评分分为轻度组31例和重度组30例,选择同期住院出生的正常足月新生儿30例作为对照组。检测受检者的血清肌酸激酶同工酶(CK-MB)、肌钙蛋白(cTnT)、左室舒张期前后径(LVDId)、左室射血分数(LVEF)、左室短轴缩短率(LVFS)、辛普森法左室射血分数(Simpson EF)、左室三腔心整体应变(GLS-LAX)、左室四腔心整体应变(GLS-A4C)、左室两腔心整体应变(GLS-A2C)、左室整体应变(GLS-AVG),分析GLS-AVG和CK-MB、cTnT三者的相关性。结果 三组间CK-MB和cTnT比较差异有统计学意义(P<0.05)。三组间性别、体重、胎龄均无统计学差异(P>0.05)。三组间LVDId、LVEF、LVFS、Simpson EF比较差异无统计学意义(P>0.05)。GLS-AVG与CK-MB呈负性相关(r=-0.515,P=0.000),GLS-AVG与cTnT呈负性相关(r=-0.912,P=0.000)。结论 GLS-AVG与CK-MB、cTnT具有相关性,GLS-AVG可作为窒息新生儿心肌损害早期诊断指标。 相似文献
14.
15.
Major depressive disorder and other neuropsychiatric disorders are often managed with long-term use of antidepressant medication. Fluoxetine, an SSRI antidepressant, is widely used as a first-line treatment for neuropsychiatric disorders. However, fluoxetine has also been shown to increase the risk of metabolic diseases such as non-alcoholic fatty liver disease. Fluoxetine has been shown to increase hepatic lipid accumulation in vivo and in vitro. In addition, fluoxetine has been shown to alter the production of prostaglandins which have also been implicated in the development of non-alcoholic fatty liver disease. The goal of this study was to assess the effect of fluoxetine exposure on the prostaglandin biosynthetic pathway and lipid accumulation in a hepatic cell line (H4-II-E-C3 cells). Fluoxetine treatment increased mRNA expression of prostaglandin biosynthetic enzymes (Ptgs1, Ptgs2, and Ptgds), PPAR gamma (Pparg), and PPAR gamma downstream targets involved in fatty acid uptake (Cd36, Fatp2, and Fatp5) as well as production of 15-deoxy-Δ12,14PGJ2 a PPAR gamma ligand. The effects of fluoxetine to induce lipid accumulation were attenuated with a PTGS1 specific inhibitor (SC-560), whereas inhibition of PTGS2 had no effect. Moreover, SC-560 attenuated 15-deoxy-Δ12,14PGJ2 production and expression of PPAR gamma downstream target genes. Taken together these results suggest that fluoxetine-induced lipid abnormalities appear to be mediated via PTGS1 and its downstream product 15d-PGJ2 and suggest a novel therapeutic target to prevent some of the adverse effects of fluoxetine treatment. 相似文献
16.
《Cancer radiothérapie》2022,26(8):1034-1044
PurposeAssess the feasibility of a randomized controlled trial (RCT) exploring the use of medical imaging as a therapeutic education (TPE) intervention in external radiation therapy.Materials and methodsExperimental feasibility trial of “RCT” type carried out in a single-center, between November 2019 and March 2020, following adult patients treated by thoracic radiotherapy. In addition to the information usually given, the experimental group benefited from an intervention consisting in the visualization of their own medical images using the open-source software “Stone of Orthanc”.ResultsForty-nine patients were recruited with a refusal rate of 8.16% (4/49). 20 patients were withdrawn from the study for health reasons (COVID), 10 for medical reasons. All the remaining 15 participants completed the process. Although not significant, the experimental group showed a median gain in the perception of knowledge compared to the control group (+ 1.9 (1.6 – 2.2)) vs (+ 1.4 (1.4 – 1.8)), as well as a decrease in scores related to anxiety (? 3.0 (?4.5 - (?2.0)) vs ? 1.0 (?5.0 - 0.0)) and emotional distress ((? 5.0 (? 7.5 - (? 3.5)) vs (? 2.0 (? 5.0 - (? 1.0)) A significant reduction (p = 0.043) is observed for the depression score ((? 2.0 (?3.0 - (?1.5)) vs (0.0 (0.0 – 0.0)).ConclusionThis study demonstrates the feasibility of the project, with promising preliminary results. Some adaptations in order to conduct a larger-scale RCT are highlighted. 相似文献
17.
18.
目的:运用新型光学生物测量仪IOL Master 700测量白内障超声乳化手术前后眼部生物学参数的变化,并探讨人工晶状体(IOL)屈光度数计算公式的选择。
方法:前瞻性研究。收集2021-01/06在苏州大学附属第一医院就诊的白内障患者52例57眼。术前和术后3mo使用IOL Master 700完成眼轴长度(AL)、前房深度(ACD)、角膜曲率(Km)的测量并分析。对不同IOL公式计算时预留的目标屈光值与术后3mo全自动验光仪实际屈光值结果进行比较并分析。
结果:手术前后测量的AL平均值分别为24.20±1.86、24.09±1.86mm,术后AL缩短了0.11mm; ACD值分别为3.08±0.44、4.55±0.36mm(P<0.001),术后ACD加深1.49mm; Km值分别为44.14±1.86、44.14±1.82D(P>0.05)。术前选用Barrett Universal Ⅱ公式所测结果的屈光误差最小,其次是Holladay Ⅱ及SRK/T公式,Holladay Ⅰ公式所测结果的误差最大(P<0.05)。
结论:白内障术后AL缩短以及ACD加深,度数测算时可考虑增加0.1mm的校正因子。IOL屈光度数计算公式中Barrett Universal Ⅱ公式预测性最佳,其次是Holladay Ⅱ及SRK/T公式。 相似文献
19.
The objective of the present study was the development and validation of the method for determining AMB-FUBINACA and its metabolite - AMB-FUBINACA O-desmethyl acid – in blood samples, followed by verification of the method in toxicological judicial and forensic medicine practice employing the example of post-aggression suicide. Most likely in consequence of development of adverse effects resulting in psychotic symptoms, a male being under the influence of the synthetic cannabinoid AMB-FUBINACA and the new synthetic opioid U-47700, mortally wounded his female partner and subsequently committed suicide. Identification and determination of the afore-mentioned xenobiotics in blood samples collected from the male and female victims were performed employing high performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (HPLC-ESI-MS/MS). The analytes were isolated from blood samples using the solid phase extraction (SPE) method. The blood samples collected from the male and female demonstrated respectively 110 and 196 ng/mL of AMB-FUBINACA O-desmethyl acid metabolite, 1935 and 357 ng/mL of U-47700, 250 and 200 ng/mL of N-desmethyl-U-47700, as well as 410 and 200 ng/mL of N,N-didesmethyl-U-47700. The concentration values of new psychoactive substances (NPS’s) in blood samples originating from the male and female were within the ranges encountered in cases of poisoning, including these resulting in death. Nevertheless, the evident signs of exsanguination proof that the woman was alive when she sustained lethal injuries. The presented cases illustrate the difficult to be anticipated effect exerted on the users by NPS’s. 相似文献
20.
Laura A. Huppert MD Ozge Gumusay MD Dame Idossa MD Hope S. Rugo MD 《CA: a cancer journal for clinicians》2023,73(5):480-515
Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer is defined by the presence of the estrogen receptor and/or the progesterone receptor and the absence of HER2 gene amplification. HR-positive/HER2-negative breast cancer accounts for 65%–70% of all breast cancers, and incidence increases with increasing age. Treatment varies by stage, and endocrine therapy is the mainstay of treatment in both early stage and late-stage disease. Combinations with cyclin-dependent kinase 4/6 inhibitors have reduced distant recurrence in the early stage setting and improved overall survival in the metastatic setting. Chemotherapy is used based on stage and tumor biology in the early stage setting and after endocrine resistance for advanced disease. New therapies, including novel endocrine agents and antibody-drug conjugates, are now changing the treatment landscape. With the availability of new treatment options, it is important to define the optimal sequence of treatment to maximize clinical benefit while minimizing toxicity. In this review, the authors first discuss the pathologic and molecular features of HR-positive/HER2-negative breast cancer and mechanisms of endocrine resistance. Then, they discuss current and emerging therapies for both early stage and metastatic HR-positive/HER2-negative breast cancer, including treatment algorithms based on current data. 相似文献